PCM
IMGN

Penn Capital Management’s Immunogen Inc IMGN Stock Holding History

Penn Capital Management’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-372,401
Closed -$3.33M – 312
2015
Q1 		$3.33M Buy
+372,401
New +$2.7M 0.13% 201

Other funds holding IMGN

ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Penn Capital Management's IMGN Position: Q2 2015 in Review

Penn Capital Management sold out of Immunogen Inc (IMGN) in Q2 2015, closing a stake of 372,401 shares — an estimated $3.33M sold.

Penn Capital Management first reported a position in IMGN in Q1 2015 and held it in 1 quarter. The position peaked at $3.33M in Q1 2015. 140 funds tracked by Wall St. Rank hold IMGN as of Q2 2015.

  • Penn Capital Management reported no remaining Immunogen Inc position as of Q2 2015 after selling out during the quarter.
  • Penn Capital Management sold 372,401 Immunogen Inc shares in Q2 2015, an estimated $3.33M.
  • Penn Capital Management first reported a position in Immunogen Inc in Q1 2015 and held it in 1 quarter.
  • Penn Capital Management's Immunogen Inc position peaked at $3.33M in Q1 2015.
  • 140 funds tracked by Wall St. Rank held Immunogen Inc as of Q2 2015.

Based on Penn Capital Management's 13F filing for Q2 2015, filed 12 Aug 2015.